3-(5-amino-2,4-difluorophenyl)-7-chloro-1-methyl-1,6-naphthyridin-2(1H)-one | 1012878-86-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(5-amino-2,4-difluorophenyl)-7-chloro-1-methyl-1,6-naphthyridin-2(1H)-one
• 英文别名: 3-(5-Amino-2,4-difluorophenyl)-7-chloro-1-methyl-1,6-naphthyridin-2(1H)-one；3-(5-amino-2,4-difluorophenyl)-7-chloro-1-methyl-1,6-naphthyridin-2-one
• CAS: 1012878-86-2
• 化学式: C₁₅H₁₀ClF₂N₃O
• 分子量: 321.714
• InChiKey: UHBMQMRKJNLPLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  59.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(5-amino-2,4-difluorophenyl)-7-chloro-1-methyl-1,6-naphthyridin-2(1H)-one 在 7-(4-methoxybenzyl)(methyl)amino 作用下， 以 N-甲基-4-甲氧基苄胺 为溶剂， 反应 16.0h， 以to give 7-(4-methoxybenzyl)(methyl)amino)-3-(5-amino-2,4-difluorophenyl)-1-methyl-1,6-naphthyridin-2(1H)-one (3 g, 91% yield), which的产率得到3-(5-amino-2,4-difluorophenyl)-1-methyl-1,6-naphthyridin-2(1H)-one
  参考文献：
  名称：

  Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases

  摘要：

  本发明涉及二氢萘啉和相关化合物；包含有效量的二氢萘啉或相关化合物的组合物；以及治疗或预防增生性疾病的方法，其中包括给予有效量的二氢萘啉或相关化合物。

  公开号：

  US08940756B2
• 作为产物：
  描述：

  4,6-二羟基烟酸乙酯 在 manganese(IV) oxide 、 aluminum oxide 、 potassium fluoride 、 lithium aluminium tetrahydride 、 三氯氧磷 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基乙酰胺 、 水 、 乙腈 为溶剂， 反应 16.5h， 生成 3-(5-amino-2,4-difluorophenyl)-7-chloro-1-methyl-1,6-naphthyridin-2(1H)-one
  参考文献：
  名称：

  Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases

  摘要：

  这项发明涉及二氢萘啶和相关化合物；包括有效量二氢萘啶或相关化合物的组合物；以及治疗或预防增生性疾病的方法，包括给予有效量二氢萘啶或相关化合物。

  公开号：

  US08461179B1

文献信息

• [EN] DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DIHYDRONAPHTYRIDINES ET COMPOSÉS APPARENTÉS UTILES COMME INHIBITEURS DE KINASES POUR LE TRAITEMENT DE MALADIES PROLIFÉRATIVES
  申请人：FLYNN DANIEL L

  公开号：WO2013184119A1

  公开（公告）日：2013-12-12

  The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or preventing proliferative diseases comprising the administration of an effective amount of a dihydronaphthyridine or a related compound. The present invention discloses the unexpected utility of compounds that inhibit cKIT kinase across a broad range of c-KIT mutations, including complex occurrences of primary mutations (KIT exon 9 or 11) and secondary KIT mutations (exons 13, 14, 17 and 18) that may arise in individual, refractory GIST patients. Also unexpected is the utility of compounds of the present invention to inhibit the problematic exon 17 D816V c-KIT mutation, for which there is currently no effective therapy.

  该发明涉及二氢萘啶并相关化合物；包含有效量二氢萘啶或相关化合物的组合物；以及治疗或预防增生性疾病的方法，包括给予有效量二氢萘啶或相关化合物。本发明揭示了抑制cKIT激酶的化合物在广泛范围内对c-KIT突变具有意想不到的功效，包括抑制原发性突变（KIT外显子9或11）和次级KIT突变（外显子13、14、17和18）的复杂发生，这些可能出现在个体、难治性GIST患者身上。同样令人意想不到的是本发明的化合物对抑制目前没有有效治疗的问题性外显子17 D816V c-KIT突变的功效。
• DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
  申请人：Deciphera Pharmaceuticals, Inc.

  公开号：US20140088075A1

  公开（公告）日：2014-03-27

  The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or preventing proliferative diseases comprising the administration of an effective amount of a dihydronaphthyridine or a related compound.

  本发明涉及二氢萘啉和相关化合物；包含有效量的二氢萘啉或相关化合物的组合物；以及通过给予有效量的二氢萘啉或相关化合物来治疗或预防增生性疾病的方法。
• Kinase inhibitors useful for the treatment of proliferative diseases
  申请人：Flynn L. Daniel

  公开号：US20080114006A1

  公开（公告）日：2008-05-15

  The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

  本发明涉及一种新型激酶抑制剂和调节剂化合物，用于治疗各种疾病。更具体地说，本发明涉及这样的化合物、激酶/化合物加合物、治疗疾病的方法以及合成化合物的方法。优选地，这些化合物对Raf激酶及其疾病多态性的激酶活性调节是有用的。本发明的化合物在哺乳动物癌症，特别是人类癌症，包括但不限于恶性黑色素瘤、结肠直肠癌、卵巢癌、乳头状甲状腺癌、非小细胞肺癌和间皮瘤的治疗中发挥作用。本发明的化合物也在治疗类风湿性关节炎和视网膜病变，包括糖尿病性视网膜神经病变和黄斑变性方面发挥作用。
• Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
  申请人：Deciphera Pharmaceuticals, Inc.

  公开号：US08188113B2

  公开（公告）日：2012-05-29

  The present invention relates to novel dihydropyridopyrimidinyl, dihydronaphthyridinyl, and related compounds which are kinase inhibitors and modulator useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

  本发明涉及一种新型的二氢吡啶吡嗪基，二氢萘嗪基和相关化合物，这些化合物是激酶抑制剂和调节剂，可用于治疗各种疾病。更具体地说，本发明涉及这些化合物，激酶/化合物加合物，治疗疾病的方法以及合成这些化合物的方法。优选地，这些化合物对Raf激酶及其疾病多态体的激酶活性的调节具有用处。本发明的化合物在哺乳动物癌症治疗中，特别是人类癌症治疗中，包括但不限于恶性黑色素瘤、结肠直肠癌、卵巢癌、乳头状甲状腺癌、非小细胞肺癌和间皮瘤中具有用处。本发明的化合物在类风湿性关节炎和视网膜病变治疗中也具有用处，包括糖尿病性视网膜神经病变和黄斑变性。
• KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES
  申请人：Flynn Daniel L.

  公开号：US20120289540A1

  公开（公告）日：2012-11-15

  The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

  本发明涉及新型激酶抑制剂和调节剂化合物，可用于治疗各种疾病。更具体地说，本发明涉及这种化合物、激酶/化合物加合物、治疗疾病的方法以及化合物的合成方法。优选地，这些化合物可用于调节Raf激酶及其疾病多态性的激酶活性。本发明的化合物在哺乳动物癌症治疗中特别是人类癌症治疗中，包括但不限于恶性黑色素瘤、结直肠癌、卵巢癌、乳头状甲状腺癌、非小细胞肺癌和间皮瘤等方面有用。本发明的化合物还在类风湿性关节炎和视网膜病变，包括糖尿病视网膜神经病变和黄斑变性的治疗中有用。